1-5 of 5
Marie-Claude Gagnieu, PharmD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Response to Ponatinib Is Not Related to the Drug Plasma Levels in Chronic Phase CML

Franck Emmanuel Nicolini, MD PhD, Delphine Rea, MD, Vincent Alcazer, MD, Francoise Huguet, MD, Laurence Legros, MD PhD, Gaelle Fossard, MD, Elodie Grockowiak, PhD, Stephane Morisset, Stat, Pierre Sujobert, MD PhD, Mohamad Sobh, Mauricette Michallet, MD PhD, Francois Parant, PharmD, Marie-Claude Gagnieu, PharmD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2901.
https://doi.org/10.1182/blood.V130.Suppl_1.2901.2901
Published: 2017
Journal Articles

Pegylated Interferon-Alpha 2a in Combination with Nilotinib As First-Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (Nilopeg trial). Four-Year Follow-up Results

Franck E. Nicolini, MD PhD, Gabriel Etienne, MD PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, MD, Laurence Legros, MD, Stéphane Giraudier, MD PhD, Valérie Coiteux, MD, Agnes Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, Shanti Amé, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD PhD, Marie-Claude Gagnieu, PharmD, PhD, Stéphane Morisset, Stat, Christine Pivot, PharmD, Madeleine Etienne, CRA, Francois Guilhot, MD, Stéphanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD Professor
Journal: Blood
Blood (2015) 126 (23): 1578.
https://doi.org/10.1182/blood.V126.23.1578.1578
Published: 2015
Journal Articles

Cardio-Vascular Events Occurring On Ponatinib In Chronic Phase Chronic Myeloid Leukemia Patients, Preliminary Analysis Of a Multicenter Cohort

Franck E. Nicolini, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Mael Heiblig, MD, Emilie Blond, Pharm.D, Laurence Legros, MD, PhD, Yann Guillermin, MD, Stephane Morisset, Stat., Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Jeremy Ruby, CRA student, Mohamad Sobh, Pharm.M., Gaelle Richard-Colmant, MD, Celine Fettig, Tech., Mauricette Michallet, MD, PhD, Delphine Rea, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4020.
https://doi.org/10.1182/blood.V122.21.4020.4020
Published: 2013
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

Pharmacogenomic Factors Such as the Expression of Imatinib Transporters (OCT-1, ABCB-1 and ABCG-2) at Diagnosis, OCT-1 SNPs, and Steady-State Imatinib and Desmethyl-Imatinib Trough Plasma Levels in De Novo Chronic Phase Chronic Myelogenous Leukemia, May Influence Disease Response to Imatinib

Hélène Labussière, MD, Sandrine Hayette, PhD, Kaddour Chabane, BSc, Marie-Claude Gagnieu, PharmD, Quoc-Hung Lê, MD, PhD, Isabelle Tigaud, MD, Joëlle Bernard, BSc, Fiorenza Barraco, MD, Jean-Pierre Magaud, MD, PhD, Mauricette Michallet, MD, PhD, Franck E Nicolini, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2643.
https://doi.org/10.1182/blood.V112.11.2643.2643
Published: 2008